Would you like to receive important updates about Celgene Corp like earnings dates and more?
The Year To Date (YTD) return is -16.61%.
The 52 Week Low stock price is 86.55 set on Fri, Mar 2, 2018 which is 18 days ago.
The current price per share is 2.29% above the 52 week low.
The 52 Week High stock price is $147.17 set on Mon, Oct 2, 2017 which is 169 days ago.
The current price per share is -39.85% below the 52 week high.
The All Time High stock price is $147.17 set on Mon, Oct 2, 2017 which is 169 days ago.
The current price per share is -39.85% below the all time high.
The Celgene 5 year stock chart shows the historical prices over the previous 60 months.
The Celgene 1 year stock chart shows the historical prices over the previous 12 months.
The 50 Day Moving Average is at $96.70 which is 8.45% above the stock price of $88.53.
The 200 Day Moving Average is at 117.35 which is 24.56% above the stock price of $88.53.
Because both the 50 DMA and 200 DMA are above the current stock price, this can be considered a bearish technical indicator.
Celgene Corp is a Health Care stock that trades on the NASDAQ and has a market capitalization of $67.40 Billion.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .
The EPS is $5.25.
The P/E Ratio is 17.08%.
Celgene has a relatively low price to earnings ratio compared to the overal S&P 500 average, which is about 25%.
Some investors look for very low p/e stocks with the hopes of investing in an undervalued stock. Of course, this is just one factor to consider.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Celgene Corp was Thu, Jan 25, 2018.
Since this earnings release 54 days ago, the stock price is down by -14.14%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The next Earnings Release Date is on Thu, Apr 26, 2018, which is in 37 days.2018-04-26 06:00:002018-04-26 13:00:00America/New_YorkCelgene Corp (CELG) EarningsVisit http://www.symbolsurfing.com/CELG for more information.United StatesSymbol Surfinginfo@symbolsurfing.com
CELG currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.